🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Found 0 matching trials

A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy

PHASE3

This two part, multi-center, open-label, single-arm study will evaluate the...

Status

Completed

Location

Multiple Locations

Start Date

2014-01

Trial ID

NCT02001987

Treatments Being Tested

Tocilizumab Methotrexate csDMARDs

Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis

N/A

The current study will assess the real - life effectiveness of adalimumab i...

Status

Completed

Location

Pont, Cranbrook, BC, CA /ID# 69120

Start Date

2012-02-16

Trial ID

NCT01559038

A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

PHASE3

This Phase IIIb, open-label, single-arm study will evaluate the safety, eff...

Status

Completed

Location

Aalborg Universitetshospital Nord, Reumatologisk Afdeling

Start Date

2014-05-28

Trial ID

NCT02046616

Treatments Being Tested

Tocilizumab Methotrexate Non-Biologic DMARDs

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

PHASE3

The purpose of this study is to summarize the safety and tolerability of ab...

Status

Completed

Location

Local Institution

Start Date

2005-04

Trial ID

NCT00124982

Treatments Being Tested

Abatacept Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)Anti-Tumor Necrosing Factor (TNF) Therapy

Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)

N/A

This study is designed to analyze the frequency and incidence rate of pulmo...

Status

Completed

Location

Multiple Locations

Start Date

2000-01

Trial ID

NCT02784808

Treatments Being Tested

Biological DMARDs Non-Biologic DMARDs

Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)

PHASE3

Part 1 of this trial will assess the safety and effectiveness of subcutaneo...

Status

Completed

Location

Multiple Locations

Start Date

2009-09

Trial ID

NCT00975130

Treatments Being Tested

SC golimumab IV golimumab

Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

PHASE3

Main Study: Primary Objective: Assess the long term safety of sarilumab i...

Status

Completed

Location

Investigational Site Number 840070

Start Date

2010-06-21

Trial ID

NCT01146652

Treatments Being Tested

SAR153191 (REGN88)

Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis

The main objective is to assess if a treat-to-target strategy implementing ...

Status

Recruiting

Location

Department of Rheumatology, Helse Møre og Romsdal HF

Start Date

2022-03-14

Trial ID

NCT05291819

Treatments Being Tested

Imaging informed treat-to-target Conventional treat-to-target

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

PHASE3

The primary objective of this study is to evaluate the effects of filgotini...

Status

Completed

Location

Multiple Locations

Start Date

2016-07-27

Trial ID

NCT02873936

Treatments Being Tested

Filgotinib Placebo to match filgotinib csDMARDs

A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis

PHASE3

This multicenter, open-label study will evaluate the efficacy and safety of...

Status

Completed

Location

Multiple Locations

Start Date

2013-09

Trial ID

NCT01995201

Treatments Being Tested

DMARD methotrexate tocilizumab [RoActemra/Actemra]tocilizumab [RoActemra/Actemra]tocilizumab [RoActemra/Actemra]

Previous Next